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Vaccine manufacturing processes are designed to meet present and upcoming challenges
associated with a growing vaccine market and to include multi-use facilities offering a broad
portfolio and faster reaction times in case of pandemics and emerging diseases. The final
products, from whole viruses to recombinant viral proteins, are very diverse, making standard
process strategies hardly universally applicable. Numerous factors such as cell substrate, virus
strain or expression system, medium, cultivation system, cultivation method, and scale need
consideration. Reviewing options for efficient and economical production of human vaccines,
this paper discusses basic factors relevant for viral antigen production in mammalian cells,
avian cells and insect cells. In addition, bioreactor concepts, including static systems,
single-use systems, stirred tanks and packed-beds are addressed. On this basis, methods
towards process intensification, in particular operational strategies, the use of perfusion
systems for high product yields, and steps to establish continuous processes are introduced.
KEYWORDS: animal cell culture . bioreactor systems . continuous processes . large-scale vaccine production
. process improvement . process intensification . viral vaccines
Vaccination represents the most effective strategy
to prevent infectious diseases, and vaccine
manufacturing is crucial for worldwide disease
control and eradication. Currently, > 50 cell
culture-based human viral vaccines are being
manufactured (TABLE S1 [supplementary material
can be found online at www.informahealthcare.
com/suppl/10.1586/14760584.2015.1067144]),
and many more are under development. Vacci-
nation implies the administration of attenuated
or inactivated infectious agents (or their compo-
nents) delivering antigenic structures that stimu-
late the adaptive immune system in order to
elicit an effective response against specific patho-
gens to prevent future infections.
Since the early 1940s, viral vaccines have
been produced in embryonated chicken eggs
replicating a broad variety of viruses [1]. Cur-
rently, the egg-based manufacturing method
provides more than 30 licensed human vac-
cines [2–4]. However, the production capacities
of this platform are greatly limited by the
availability of fertilized eggs. An alternative
technology relying on animal cell culture was
established in the 1950s using primary cells as
substrate for virus production. Subsequently,
in the late 1960s, continuous cell lines were
recognized as suitable hosts for human vaccine
production, but it was not until 1977 that the
first production process was licensed [5,6]. Cell
culture-based vaccine production processes
enable simple infection and harvesting steps in
defined environments with closed bioreactor
systems ensuring sterility, while further reduc-
ing biosafety risks by automation. Current
plant manufacturing capacity can be scaled up
to produce millions of vaccine doses, while
maintaining cell cultures in controlled cultiva-
tion vessels.
In this review, we discuss bioreactor con-
cepts and operational strategies for cell culture-
based processes focusing on viral vaccines for
human use. We first describe different viral
vaccine types currently produced, introduce
general concepts of cell culture-based viral
antigen production and discuss factors that
greatly affect process design. Afterwards, we
address cell cultivation in bioreactors and dis-
cuss operation modes that have enabled the
development and improvement of cell culture-
based processes for vaccine production in labo-
ratory and industrial scales.
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Crucial aspect defining the process choice
The choices of the vaccine type, the cell substrate and the pro-
duction process including bioreactor and operation mode are
crucial for successful manufacturing of human vaccines. All
these factors have a significant impact on vaccine quality, as
well as on manufacturing capacity, production volumes, process
times and product costs. Among many factors that have to be
defined, the following five aspects are of crucial importance.
Vaccine demand
Vaccine demand varies according to the spread of a virus and
its mutation rate, which may result in new circulating strains
not covered by the available vaccine. For instance, at the begin-
ning of US immunization campaigns against seasonal influenza,
up to 100 million vaccine doses are required to be produced in
a time period as short as 5–6 months [7,8], while influenza vac-
cines in case of a pandemic ideally need to be available within
a few weeks (which is not possible at the moment using estab-
lished manufacturing technologies). In contrast, vaccines
against, for example, polio or measles require a more or less
constant supply of the same vaccine strain for worldwide appli-
cation and vaccines against dengue or yellow fever are only
needed in certain regions of the world. Therefore, vaccine
demand is not only described by the number of doses pro-
duced in campaigns, but also by the time window available for
manufacturing.
Vaccine type
Vaccine types are basically defined by the component eliciting
the immune response. Such antigenic components can be live-
attenuated viruses, inactivated viruses, virus subunits, viral vec-
tors or recombinant virus-like particles/proteins. In this work,
we address these five kinds of viral vaccines and summarize
their important characteristics in TABLE 1. From this list, live-
attenuated vaccines are usually the most immunogenic and thus
require the lowest concentrations of immunogens per dose [9].
Nevertheless, viruses with a high mutation rate are unsuitable
candidates for such a vaccine type as reversion may occur dur-
ing vaccine production. Another drawback is the potentially
reduced replication of attenuated virus strains in cell culture,
which would lower process yields. In contrast, wildtype viruses
employed for manufacturing of inactivated vaccines typically
lead to higher virus yields. However, handling highly patho-
genic wildtype live viruses may require biosafety level 3 condi-
tions [10,11], and this complicates production significantly.
Recombinant vaccines allow circumventing these safety require-
ments, but are often less immunogenic and therefore require
higher antigen concentrations per dose. (Additional information
about immune response triggered by different types of vaccines
can be found in [12]).
Virus/antigen requirements for growth/expression
Manufacturing of viral vaccines typically involves the supply of
eggs or cultivation of animal/insect cells with subsequent infec-
tion. The latter step is subject to virus specific replication
characteristics in cultivation vessels (virus spreading in cell pop-
ulations, as well as virus release) determining optimal cultiva-
tion conditions, operation modes and harvest strategies. One
example is the infection dynamics of Modified Vaccinia Ankara
(MVA) virus in continuous cell lines, which remains attached
to the cell membrane after budding and therefore requires
direct cell-to-cell contact to spread infection to neighboring
cells [13,14]. Recent adaptation attempts generated successfully a
new genotype of MVA virus that propagates in single sus-
pended avian cell cultures, facilitating the manufacturing pro-
cess [15,16]. Some viruses, like rotavirus, influenza virus or
Sendai virus, require previous protease treatment to increase
their infectivity in cell culture [17–20]; whereas others have spe-
cific demands regarding their host cells, such as polio virus,
which only proliferates in primate-derived cells [21]; the Mink
enteritis virus (MEV), which only multiplies in mitotic cells [22]
or the influenza virus, which only binds to cells with receptors
containing sialic acid residues [23].
Host cell characteristics & growth requirements
Different cell substrates possess diverse characteristics that
make them suitable for specific applications in vaccine pro-
duction (see cell substrates used for different vaccine types
in TABLE 1 and in (TABLE S1) for approved vaccines). Therefore,
the right cell line and optimal process parameter conditions
(e.g., temperature, pH value, dissolved oxygen concentration,
medium composition, etc.) strongly affecting cell growth
and virus replication must be selected, to ensure high viral
yield. In the following section, cell substrates are divided
into two groups. First, human/higher animal cell substrates
(human, avian and mammalian cell lines), which are mainly
used for whole virus replication; second, insect cell sub-
strates (lepidopteran and dipteran cell lines), which are
mainly used in recombinant antigen and virus-like particle
(VLP) production.
Human & higher animal cell lines
Manufacturing of many cell culture-based human vaccines
employs primary culture of 10- 11-day-old chicken embryo
fibroblasts [2,3,24]. Hence, the production capacity depends
entirely on the supply of embryonated eggs, which may be
endangered by outbreaks related to avian pathogens. Primary
monkey cells (from Chlorocebus aethiops) are also commonly
employed for manufacturing of human vaccines. However, in
addition to bioethical implications, donor animals may host
potential pathogens to humans and must be strictly monitored,
increasing process complexity [6].
Continuous cell lines circumvent the previously mentioned
drawbacks related to the use of primary cells and are therefore
the preferred substrates in current cell-based manufacturing
processes (TABLE S1) [2–4]. More recent approaches regarding con-
tinuous cell line development aim on directed generation of
cell lines (so called “designer cell lines”) by specific mutations
to increase cell specific virus yields [25]. Most commercial
virus production processes, however, still rely on the Vero,
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MDCK, MRC-5 and WI-38 continuous cell lines, which
maintain an anchorage-dependent growth. In addition, the
human cell lines HEK293 and PER.C6, as well as the avian
cell lines AGE1.CR and EB66, are employed at research or
clinical scale for vaccine candidate development [26–31]. They
have been successfully adapted to grow in suspension, facilitat-
ing cultivation of cells and scale-up in vaccine produc-
tion [6,26–28,32–34]. Most human and higher animal cells also
still require complex media, frequently enriched with fetal calf
serum, for optimum growth and high virus yields. This
increases not only production costs and batch-to-batch varia-
tions, but also involves the risk of introducing adventitious
agents. Media development enabled the cultivation of
HEK293, MDCK and Vero cells in serum-free media achiev-
ing comparable yields of human influenza virus, equine influ-
enza virus and rabies virus, respectively, to those obtained in
serum supplemented media [26,35,36]. Comparing different cell
lines under this aspect, human PER.C6 cells grown in serum-
free media led to higher cell-specific yields of polio virus
(types 1, 2 and 3) than Vero cells grown in serum-containing
medium [28]. Accordingly, an increasing number of cell-based
vaccine candidates (e.g., against yellow fever, polio, human
and avian influenza, dengue and respiratory syncytial virus
(RSV)) are produced in continuous cell lines [37–43].
Insect cells
The use of insect cell cultures for human recombinant vaccine
manufacturing is an upcoming strategy, and so far Cervarix
(vaccine against certain types of cancer-causing human papillo-
maviruses) and Flublok (influenza vaccine) have been approved
for human use (see TABLE S1). Insect cells can be easily cultivated
in suspension cultures using serum-free media, representing an
attractive substrate fulfilling current criteria for vaccine develop-
ment [44–46]. In order to produce vaccines using lepidopteran
cell lines (such as Sf9, Sf21, Sf+ and H5), cells are infected
with engineered baculoviruses carrying the heterologous genes
of the desired antigens. In the insect cell-baculovirus expression
system, baculoviruses work as viral vectors for recombinant pro-
tein expression, while they replicate inside infected insect cells.
As a consequence, the formation of new baculovirus particles as
by-product represents an important concern in downstream
processing of VLP vaccines. In this regard, a vector incapable
producing new baculovirus particles has also been developed [47].
Remarkably, this drawback has turned into new applications, as
baculoviruses do not represent a risk for human health, and the
use of such viruses as vector-based vaccines and in gene therapy
has also been proved as safe [48–50]. Recombinant vaccine pro-
duction in the dipteran cell line Schneider’s Drosophila mela-
nogaster (S2) does not involve viral infection, but the
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establishment of stable producer cells by cell engineering. Based
on this technology, stably modified H5 cells have recently been
developed for Japanese encephalitis vaccine production [51].
An important drawback of insect cells is the difficultly to
express membrane proteins and secreted glycoproteins at appro-
priate levels, which are both relevant antigens for vaccine devel-
opment (reviewed in [52]). Additionally, insect cells cannot
synthesize the complex glycan structures typical for mammalian
cells. Despite this limitation, several glycosylated vaccine candi-
dates produced in insect cells such as those against Chikungu-
nya virus, influenza virus, RSV, enterovirus 71 (EV71) and
dengue virus have elicited an antibody response or protection
during virus challenge in animal model systems [53–61]. To date,
production processes of human vaccine candidates against the
above-mentioned wildtype viruses as well as malaria, avian
influenza, measles and Ebola viruses are under development
[45,46,58,62–70].
Virus/antigen stability
Single or multiple harvest strategies (TABLE 2) are applied to avoid
virus/antigen degradation in upstream processing, which is
mainly caused by the release of cellular proteases after cell lysis
and low thermostabilities. A simple and quick method adjusted
to the product properties is therefore crucial. One example is
given by hollow-fiber-based perfusion systems enabling selective
separation and further processing of the product-containing
medium. Operation modes retaining only cells or even viruses
while removing proteases with spent medium are available. If
the virus/antigen is produced at almost constant rates (mostly
for slow/non-lytic viruses and virus-free systems), multiple or
continuous harvesting steps can improve the process. After har-
vesting, further clarification steps are commonly performed
batchwise by filtration or by the use of other separation
methods [71].
Once the production process has been defined based on the
abovementioned aspects, the appropriate cultivation systems
can be chosen. Undoubtedly, the most important advantages of
vaccine manufacturing in cell culture are those linked directly
to the use of bioreactors: the use of closed systems including
harvest vessels and pipework; the possibility to establish fully
controlled processes, to improve robust-
ness and to ensure product quality; the
option to employ advanced cultivation
methods, to maximize process yields by
controlling cell growth, virus replication
or protein expression through optimized
operating parameters; the possibility to
increase the production capacity accord-
ing to market demands or requirements
for clinical trials and, finally, the poten-
tial to reduce process costs and facility
space. In the next sections, we will dis-
cuss the most common options for vac-
cine production in bioreactors and
operation modes, to achieve these goals.
Vaccine production in static systems
Over the past few decades, a variety of large-scale devices for
static cultivation of adherent cell lines have been
developed (TABLE 3). Most of the cultivation systems applied to
vaccine production offer restricted inoculation and harvesting
options, with limited monitoring of pH and oxygen and lim-
ited control of cultivations parameters, such as temperature and
sometimes feeding rates. However, due to the simplicity and
robustness of such systems some vaccine manufacturing pro-
cesses still rely on these cultivation systems (e.g., the human
varicella vaccine Varivax produced in MRC-5 cells (Merck)
and the influenza vaccines Celvapan and Vepacel produced in
Vero cells (Baxter) [72]). Accordingly, a large amount of exper-
tise in handling such systems and optimizing corresponding
production processes has been accumulated over the years. In
several cases, standardization of processes and modularization
of unit operations has resulted in highly competitive products
regarding costs per vaccine dose, for example for influenza vac-
cines for human use. Such systems (TABLE 3) have also found
their application in the generation of cell seeds for large-scale
production in microcarrier systems or the generation of virus
seeds to infect bioreactors. In the following, general properties
of static systems comprising roller bottles and enlarged multi-
layer systems including automated solutions will be briefly
discussed.
Roller bottles
Uncontrolled roller bottles (RBs) are commonly employed at
low scale or at pre-culture steps to inoculate small bioreactors
with microcarriers. Handling large numbers of RBs involves
not only a lot of manual (or robotic) work and carries a rela-
tively high sterility risk, when performing medium exchange,
washing steps, cell harvest and infection, but also requires the
use of dedicated clean rooms and a large capacity of incubators.
Therefore, the scale-up of adherent cells based on RBs may
become cost and labor intensive and is then an issue to be con-
sidered. In this regard, fully automatized solutions are available
(for instance Cellmate from Tap Biosystems [73] or RollerCell
40 from Synthecon [74]), which allow handling of large
Table 2. Comparison of single and multiple harvest strategies applied
in viral vaccine production.
Single harvest Multiple harvests
Virus replication in primary cells (e.g., rabies and
poliovirus)
Virus infection at maximum cell concentration
(e.g., MVA, influenza virus)
Viruses with a high mutation rate (RNA viruses)
Viruses that accumulate DIPs at high rates (e.g.,
influenza virus, baculovirus)
Unstable viruses (e.g., infectious particles for live
attenuated vaccines)
Slow lytic viruses (e.g., MVA)
Non-lytic viruses
Virus infection at cell inoculation (e.g.,
MEV)
Low yield viruses (e.g., live-attenuated
viruses, HCV)
Virus-free systems (e.g., stably
modified S2 or H5 insect cells)
DIPs: Defective interfering particles; HCV: Hepatitis C virus; MEV: Mink enteritis virus; MVA: Modified vaccinia
Ankara virus.
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numbers of RBs under sterile conditions, while also reducing
the risk of operator handling errors. Using this technology,
contract manufacturers already offer automated handling of up
to 1000 RBs per batch (IDT Biologika) [75]. Despite the above-
mentioned drawbacks, RBs remain a practical and low-cost
option for cell culture at laboratory scale and for large-scale
manufacturing of products licensed many years ago or live-
attenuated vaccines with low or local market demand.
Multilayer cultivation systems
Multilayer cultivation systems with increased surface-areas show
a better footprint and easier handling in large-scale production
compared to RBs (listed in TABLE 3) [76,77]. Stacked devices are,
for example, the CellCube (Corning), the CellSTACK (Corn-
ing) and the Cell Factory (Thermo Scientific), all reducing
incubator space and the need of manual handling. The large
surface solution CellCubes (85,000 cm2 and 7.3 l total
medium per batch) was used to cultivate MRC-5 cells for
hepatitis A virus production [78]. One extensible CellCube unit
replaces 50 RBs (1750 cm2) and additionally offers medium
recirculation and medium exchange for better aeration and sta-
ble pH values. The increased process control by small addi-
tional expenditure has clear advantages over other more
conventional static systems, such as RBs. The CellSTACK
(6260 cm2 and 1 l total medium) consists of multilayer
T-flasks and has been demonstrated at pilot scale for the pro-
duction of HIV pseudovirions via transient transfection of
HEK293T cells [79]. One module can be easily expanded by
the attachment of three further stacks, which can be handled
simultaneously. Another alternative is given by Cell Factories
(25,280 cm2), which has shown a 23-fold yield increase of
bovine RSV vaccine in the bovine cell line NM57 in compari-
son to RBs with comparable total surface area [80].
Due to the high cells/volume ratios (TABLE 3), fewer multilayer
systems and less working volumes are required for large-scale
production processes, replacing a large amount of RBs.









































































































†If two values are given, they present the minimum and maximum areas available, together with respective cell yields and working volumes. Within this range, other
areas are equally available.
‡(Cell yield(vessel x)/working volume(vessel x))/ (Cell yield(T175)/working volume(T175)); the higher the value, the better the volume specific cell yield.
Grey rows: packed-bed reactors.
§Data given by Corning [76].
¶Handling of Cell Factory System requires special incubator. Automated systems for seeding, harvesting, and cell detachment are available. Data given by Nunc [77].
#Calculated from data given by CESCO BioProducts [98].
††Calculated from data given by Eppendorf; bioreactor pre-loaded with FibraCel microcarriers [99].
‡‡Data given by Pall [100].
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However, handling of numerous multilayer systems running in
parallel, with working volumes of up to 8 l per unit, clearly
requires automated handling. This can be provided for Cell
Factories (Nunc, Thermo Scientific) encompassing automatic
filling, emptying and even shaking for cell detachment [81], but
the investment significantly increases procurement costs. In
comparison to bioreactors, multilayer systems require a lower
operator skill level and lower investment costs, so that their
implementation at large scale may still constitute an affordable
and competitive option for manufacturers with reduced facility
complexity.
Vaccine production in bioreactors
Bioreactors either as glass vessels, stainless steel tanks or single
use systems have clear advantages over handling static culture
vessels with limited control possibilities. Many options are
available to adjust process parameters for improved cell growth
and virus production and to reduce operational costs as well as
manufacturing time, all critical goals in vaccine manufacturing.
The principal advantage of bioreactors and the reason for their
successful implementation in vaccine manufacturing processes is
the unsurpassed scale-up advantage. Furthermore, the use of
controlled bioreactors enables scale-down approaches of estab-
lished processes, to perform broad optimization studies and the
subsequent implementation of identified parameters at indus-
trial scales. The preservation of determined dimensionless quan-
tities was successfully performed for an inactivated polio
vaccine process during the reduction of the production volume
from 750 to 2.5 l, allowing comparable cell growth and virus
yields at both scales [82]. Another scale-down approach was
applied to an established manufacturing process for live-
attenuated polio vaccine with adherent Vero cells on Cytodex-1
microcarriers [39]. At laboratory scale, poliovirus production was
evaluated under different culture temperatures, optimal parame-
ters were determined and, based on these laboratory-scale
results, the process was subsequently successfully scaled up to
350 l. Such optimization resulted in a modified process applied
to a new inactivated polio vaccine candidate, which is currently
being evaluated in clinical trials.
Today, a variety of stirred-tank bioreactors (STRs) with well-
characterized hydrodynamic properties are available for cell cul-
ture, enabling seamless transfer of cultivation processes onto
the several thousand liter scale. In order to maintain most suit-
able cultivation conditions over such scale, new equipment is
continuously developed to keep shear forces in large-scale bio-
reactors low, while still enabling high oxygen transfer rates [83].
In the following, different bioreactor concepts and operation
modes in cell culture-based vaccine production are discussed.
Vaccine production in batch mode & process
intensification options
Bioreactors in cell culture-derived vaccine production are
mainly operated in discontinuous batch cultivation mode. This
operation mode constitutes the simplest method to grow adher-
ent and suspension cell lines, to manufacture a desired product.
It requires low instrumental and operational intervention and is
therefore typically adopted for its ease of implementation and
process robustness [84]. Its wide adaptation in industry mainly
derives from relatively good virus yield coefficients and high
nutrient consumption, reducing growth media waste, the major
cost-driving component. However, due to increasing vaccine
demands and reduced production costs, process intensification
through fed-batch or perfusion systems aims on higher cell
concentrations and increased volumetric virus yields. Less biore-
actor runs for certain products give the manufacturer the
opportunity to extend their vaccine portfolio. The general strat-
egy is the full exploitation of growth media by reducing nutri-
ent limitations during cell growth and virus replication, to
maintain or even increase cell-specific productivities over
extended time periods. In the following section, options for
process intensification in bioreactors are described for adherent
and suspension cells.
Adherent cells on microcarriers
A key step toward large-scale production of vaccines was the
development of microcarrier processes, mainly driven by van
Wezel [85]. Today, adherent cells like Vero, MRC-5 and
WI-38 are grown routinely on microcarriers in quasi-
suspension conditions maintained in standard bioreactors with
low agitation speed or in wave bioreactors with appropriate
rocking-motion [82,86–88]. Microcarrier materials are typically
porous (macroporous) or non-porous beads made of glass, plas-
tic or dextran. More recently, improvements in virus yield
compared to conventional static systems have been achieved.
One example is the propagation of Mink enteritis virus (MEV)
in mitotic adherent embryonic feline lung fibroblasts (E-FL)
cultivated on Cytodex-1 microcarriers. The investigated process
was performed in a wave bioreactor (10 l working volume),
which replaced a total of 600 RBs (1750 cm2) due to its higher
productivity [22]. Another example is given by an optimized
rabies virus production process in adherent Vero cells growing
at Cytodex-1 microcarrier concentrations up to 25 g/L in a
STR (30 l working volume) in perfusion mode. Using a
decanting column and a shear-reduced cell lift impeller, this
system allowed for production of 1 million vaccine doses annu-
ally under GMP conditions [89]. Examples of recently devel-
oped large-scale application can be found for vaccines against
poliomyelitis [39,90] and influenza (H5N1) diseases [91].
Microcarrier cultivations allow the easy separation of media
from cells during the process, by reducing agitation speed to
favor bead sedimentation. This facilitates the establishment of
advanced process operations to improve cell growth and to
increase virus yields. For instance, media exchange and nutrient
feeding strategies were used to increase concentration of Vero
cells grown on Cytodex-1 microcarriers by 80%, while polio
virus type 1, 2 and 3 D-antigen yields were improved by 100,
64 and 76%, respectively, in comparison to batch cultures [90].
Alternatively, volume reduction before virus infection can result
in an increased virus–cell contact supporting virus adsorption
and therefore help to optimize virus yields [92,93]. Another
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approach comprises a cell dilution step during virus production
(a so-called volume expanded fed-batch) to increase virus titers,
as described for Parapoxvirus ovis production by factor 40 in
bovine kidney cells growing on Cytodex-3 microcarriers [94].
A general drawback of microcarrier-based processes, as men-
tioned earlier, is the need for high cell numbers to inoculate
vessels with microcarrier concentrations at increasing volumes.
In addition, the use of serum-free (SF) media often results in
poor cell attachment [95], so recombinant adhesion factors are
usually supplemented to facilitate cell binding. Another con-
straint of bead-based cultivations can emerge, when the recov-
ery of intracellular viruses requires cellular disruption or when
macroporous carriers entrap cells and make them difficult to
access [96]. In addition, microcarriers are comparatively expen-
sive and typically not recycled after use. Nevertheless, new
microcarriers are still introduced to the market. For instance, a
new low-cost microcarrier material made out of plant-derived
polysaccharides enabled to achieve rabies virus titers in Vero
cells similar to those obtained in Cytodex-1 microcarrier cul-
ture in a stirred bioreactor, with a sixfold lower cost [97]. As
discussed previously however, the main drawback of microcar-
rier cultures remains the difficulty to scale-up processes. These
are, in particular, technical challenges involving harvest of con-
fluent cells and efficient bead-to-bead transfer. Few cells like an
adherent bovine kidney cell (BK KL3A) allow direct cell expan-
sion, where cells attach to freshly added microcarriers in the
next process scale [94]. In most cases, more sophisticated proc-
essing steps are required to avoid cell damage during trypsiniza-
tion and to obtain high plating efficiency at the next passage.
Another aspect to consider is the intensification of
microcarrier-based processes. Process intensification based on
higher microcarrier concentrations to increase surface areas
requires higher cell numbers for inoculation which, in turn,
results in higher demands of culture seeds in the process train.
In addition, a higher power input may be required to keep
microcarriers in suspension, which increases the shear stress.
Furthermore, microcarrier concentrations cannot be arbitrarily
increased as friction between beads can lead to cell
abrasion [92].
However, certain viruses relevant for vaccine production can
only be produced at acceptable yields in adherent cell lines and
quasi-suspension culture on microcarriers remains as a viable
cultivation option for vaccine manufacturing.
Adherent cells in packed-bed bioreactor
An alternative system to microcarrier suspension cultures is the
use of disposable fixed-bed systems or packed-bed systems,
which protect adherent cells against mechanical stress. Such cul-
tivation vessels typically rely on highly porous polyester micro-
fiber carriers or discs delivering very large surface
matrices (TABLE 3) [98–100]. For example, the iCELLis 1000
provides surface areas of up to 1000 m2 in a 25 l fixed-bed
volume perfused with 70 l medium stored in an additional ves-
sel. As cells grow and expand on such matrices, very high cell
concentrations can be reached from low initial cell numbers,
facilitating inoculum preparations. Obviously, high cell concen-
trations require intensive bioreactor-volume exchanges to guar-
antee sufficient nutrient supply of cells and to remove waste
metabolites such as lactate. While porous surfaces, packing den-
sity and bioreactor volume exchange rate are rarely limiting fac-
tors for achieving maximum cell concentrations in such
systems, mass transfer rates into macropores, that is, the volu-
metric oxygen transfer coefficient (kLa), often limit cell
growth [101]. Nevertheless, the iCELLis system mentioned above
enabled confluent cell growth on a surface of about 133 m2
replacing 760 RBs (each 1750 cm2) or one 85 l bioreactor
with 3 g/L Cytodex-1 microcarriers with respect to similar
growth surfaces [102].
Macroporous supports have also been used to demonstrate
their potential use in viral vaccine manufacturing. In
laboratory-scale experiments, adherent MRC-5 cells grown in
an iCELLis Nano packed-bed (850 cm2, 200 ml fixed-bed,
1000 ml medium reservoir) produced hepatitis A and Chikun-
gunya viruses at yields that were nearly twofold higher than in
RBs, while media consumption was partially reduced [103]. Fur-
ther, Vero cells were cultivated on Fibra-Cel discs in perfusion
mode performing multiple harvests to produce vaccines against
rabies. Higher cell concentrations as well as virus titers were
obtained compared to 500 mL spinner cultures using Cytodex-
1 microcarriers [104]. Additionally, other packed-bed systems
with newly developed micro- or macropores have become avail-
able, such as the BioNOC II polyester carriers from Cesco
(e.g., case studies on EV71 and rabies virus produced in Vero
cells) or the AmProtein Current Perfusion Bioreactor with
polymer fiber paper carriers for influenza virus production [105].
Besides the biological compatibility to maintain cell cultures
and virus replication, disposable bed bioreactors deliver pre-
validated and pre-characterized cultivation vessels with easy and
flexible handling, saving hands-on time. Multiple packed-bed
bioreactors allow on-line monitoring of culture parameters such
as pH, dissolved oxygen, temperature and, more importantly,
cell growth or progress of infection through permittivity sensors
for viable cell concentration determination [106]. However, diffi-
culties related to the harvest of viable cells from rough surfaces
and porous matrixes exclude packed-bed reactors from seed
train purposes [107]. Overall, while cultivation of adherent cells
is broadly established and often a must for achieving product
yields required for economic production of vaccines, the devel-
opment of suspension cell lines with high cell-specific virus
production would be preferred for most large-scale
applications.
Batch cultivation of suspension cells
Conventionally, suspension cell lines are generated through an
adaptation process, where adherent cells lose their anchorage
dependence by occasional mutation, so that the new cell lineage
starts to proliferate freely in medium. At small volumes of up
to 500 ml, suspension cells are usually cultivated in shake
flasks, whereas wave bioreactors or STRs are handy options for
large scale. The main advantage of suspension cultures is their
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easy expansion by simple volume increase, enabling the full
exploitation of bioreactor capacities of up to 20,000 l, as dem-
onstrated for influenza vaccine production with PER.
C6 cells [108]. Furthermore, like quasi-suspension culture with
microcarriers, suspension cultures are amenable for process
automation as well as for easy regulation and control of opti-
mized conditions, resulting in being the current choice for
most large-scale biomanufacturing processes [109].
Despite the adaptation to growth in suspension culture, cells
can keep their susceptibility and permissiveness to allow effi-
cient virus replication. This was demonstrated for a relevant
large-scale MDCK cell line adapted to suspension that yielded
similar cell-specific influenza virus titers in comparison to the
parental adherent cell line [6]. Infection studies with influenza
A/PR/8/34 H1N1 in a 1 l bioreactor showed that the viruses
spread efficiently over the whole cell population, even at a very
low multiplicity of infection of 10–5 (based on TCID50). The
first approved cell culture-based influenza vaccines, Optaflu
and Flucelvax (Novartis), produced in a proprietary MDCK
suspension cells, are based on such findings. Both vaccines
could show similar efficiency and safety in comparison to tradi-
tional egg-based vaccines [32,110].
Cultivation of EB66 and AGE1.CR.pIX avian cells in 200 l
disposable stirred tanks to produce MVA vector-based vaccine
candidates against tuberculosis and Ebola, respectively, are
recent examples of the input of suspension cultures in current
process development [14,31]. Cell adaptation to suspension
growth is not every time as straightforward and successful as
previously described. More recent studies have indicated that
during adaptation, certain cell lines may also change their
expression of surface receptors, which then affects their suscep-
tibility to viral infection [38]. Moreover, not all human, avian
or animal cell lines can be adapted to robust growth in suspen-
sion retaining permissiveness to viral infection [107]. In this
regard, insect cell cultures constitute a robust platform and are
easily maintainable as suspension cells in conventional bioreac-
tors producing a broad range of recombinant vaccines
(reviewed in [111,112]). This was demonstrated for the approved
recombinant influenza vaccine Flublok (Protein Sciences Cor-
poration) produced in SF+ insect cells at 2500 l working vol-
ume. Due to the high scalability and efficient HA expression at
adequate volumetric yields (detail unknown), large-scale
production has been recently projected to 15,000 l, without
anticipated compromises in final yields or product quality [113].
Process intensification in suspension cultures
There are several strategies to optimize and modify batch culti-
vations maintaining suspension cells in laboratory scale.
Although new technologies are intensively investigated, most
intensification processes could not yet find broad application in
commercial production. The simplest strategy for process opti-
mization is, first, the fed-batch mode proving a simple feed
strategy to improve cell growth, cell viability and life time of
cells resulting in higher virus yields. This was successfully
employed in insect cell cultures where, for instance, Sf9 cell
concentrations increased threefold resulting in higher volumet-
ric yields of the recombinant dengue NS1 protein [114]. Similar
improvement was shown with a 30% increased recombinant
expression yield of the reticulocyte binding protein PfRh5 as
antigen for malaria vaccine in S2 cells [64], and 2.3-fold increase
in volumetric yields of recombinant influenza vaccines pro-
duced in Sf+ cells [115]. Second, perfusion systems can be used
feeding fresh medium, while withdrawing spent medium to
achieve higher cell concentrations and extended run times
beyond typical upper limits of batch and fed-batch processes.
Newer perfusion systems are based on external hollow-fiber
modules with certain molecular weight cut-offs, retaining sus-
pension cells, and optionally viruses, in the cultivation vessel.
These cell separation devices mainly work in cross flow mode
with either constant, pulsed or alternating flow directions
avoiding membrane fouling and promoting disaggregation of
cell clumps due to increased shear forces. The exchange of
medium prevents the depletion of nutrients and removes inhib-
itory metabolites or proteins, while cells concentrate in the cul-
tivation broth. This may help to avoid reduced cell-specific
virus yields observed in batch processes at high cell concentra-
tions for which the mechanism is not yet completely under-
stood (so-called “high cell density effect”) [116]. Overcoming
this issue with perfusion systems, increasing volumetric yields
lead to reduced working volumes by multiple factors of up to
100, without decreasing product quantity [117]. While current
cell concentrations of batch processes in commercial vaccine
production range between 2 and 20  106 cells/ml, perfusion
systems target up to 8  107 cells/ml with run times of
90 days and longer [118]. Record-breaking appears recent pub-
lished PER.C6 cell concentrations of 3.6  108 cells/ml in
alternating tangential flow perfusion systems (ATF, Refine)
within 14 days [119]. This benefit gives the option to operate a
single perfusion bioreactor as constant seed reactor for multiple
batch processes in parallel or even time-shifted (hybrid process-
ing) [120]. Through this implementation, whole manufacturing
chains can be shortened, as already demonstrated for antibody
expression processes employing CHO cells. The direct inocula-
tion from highly concentrated perfusion bioreactors into
production vessels reduced working volumes and numbers of
pre-culture steps saving several days [121]. This strategy can be
readily applied in processes for vaccine production. In addition,
continuous media exchanges enabling stable and high cell con-
centrations over an extended time period can be highly advan-
tageous for recombinant vaccine production in virus-free
systems, such as those based on S2 and H5 stably modified
insect cell lines.
In comparison to batch or fed-batch systems, prolonged cul-
tivation times may involve relatively elaborate and time-
consuming licensing procedures, for example, demonstration of
long-term passage stability, definition of a new lot and batch
system. However, some companies like Crucell Holland con-
cluded that these difficulties are well worth the effort and
implemented high cell density cultivation processes for inacti-
vated polio production using PER.C6 suspension cells [41,122,123].
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In this set-up, applying ATF modules to 500 l stirred bioreac-
tors allowed achieving similar cell numbers to those reachable
in 10,000 l non-perfused bioreactors, representing a 20-fold
decrease of production volumes for vaccine capacities [41].
Laboratory-scale experiments gave further examples for its suc-
cessful process intensification of AGE1.CR and human CAP
cells infected with various influenza A virus strains that reached
similar cell-specific virus yields in comparison to batch pro-
cesses [124,125]. Of particular interest is the constant cell-specific
virus yield maintained for AGE1.CR cells at concentrations as
high as 48  106 cells/ml, overcoming high cell density issues
due to permanent media exchange [124]. Also insect cells
responded positively onto perfusion systems. S2 insect cell cul-
tivations have been optimized through perfusion systems,
resulting in a 12-fold increase in the expression yield of the
recombinant PfRh5 protein during a 9-day perfusion run in
comparison to its fed-batch process [64].
However, perfusion systems have certainly also critical disad-
vantages explaining their rare commercial application. Besides
limited passage numbers of approved cell lines, and higher
complexities resulting in increased sterility risks (which is con-
trollable with today’s standards), perfusion systems cannot be
performed at optimal medium exchange rates yet. Complex
biological systems, like herein discussed cells, their impact on
stress conditions and their variability are not fully understood
and complicate media development (basal growth and perfu-
sion medium), reflecting best nutrient concentrations and fac-
tors. This leads, in comparison to batch cultivations, to higher
and therefore less efficient medium consumption.
Vaccine production in continuous mode
Continuous bioreactor operations aim to improve manufactur-
ing by increasing process efficiency and plant utilization, and
to implement automated process control, while maintaining
flexibility and product quality [117,126]. Conversely to batch
mode processes, the concept of continuous manufacturing
describes an ongoing flow of material in and out of the biore-
actor, altogether aiming at a constant harvest of virus without
restarting the system. This strategy requires less manual opera-
tion during the process and avoids down-times for vessel
cleaning, maintenance, calibration of sensors and sterilization
(last-mentioned in cases of STRs). In addition, continuous pro-
cesses are expected to keep by-product concentrations (e.g.,
proteases) at negligible concentrations, and to handle labile
products rapidly [127], as most viruses lose their infectivity at
higher temperatures and proteins forfeit their functionality.
Since several years, regulatory agencies such as the US FDA
encourage the establishment of cell-based continuous
manufacturing processes, which has been the subject of serious
attempts for recombinant protein production in CHO
cells [117,126–128]. Whether similar concepts can be transferred to
cell-based virus manufacturing remains to be clarified as muta-
tion rates of cells and viruses restricted their temporal use to
currently 20 and 5 passages, respectively (including master
seed). Further, and most importantly, is the uncertainty of
possible virus vaccine generation in continuous processes from
a biological point of view and the possibility to reach a steady
state in any infected culture. The effect on virus antigenicity or
virulence due to mutation accumulation during extended peri-
ods of viral replication remains as concern (reviewed in [129]).
Technical challenges in process design and operation also lead
to difficulties in scalability, process robustness and process vali-
dation. In addition, regulatory acceptance is not clear, as autho-
rization requirements have not been defined so far.
Overcoming technical challenges, laboratory-scale investiga-
tions with a continuous process for influenza A virus produc-
tion using a two-stage stirred-tank bioreactor system were
undertaken [130]. AGE1.CR cells grew constantly in a first bio-
reactor and were fed into a second bioreactor for influenza A
virus infection and propagation. The harvest was removed con-
tinuously over a time period of 17 days. However, in the virus
production bioreactor, neither the cell concentration nor the
virus titers reached a steady state, but fluctuated periodically (in
inverse correlation) during cultivation time. This could be
explained by accumulation of defective interfering particles
(DIPs) in the bioreactor, leading to a drop in infectious viral
titer. As a result, the cell-specific virus yield was reduced in
comparison to batch processes. DIP accumulation was also
observed in a continuous process of the insect cell line
Se301 infecting with baculovirus which, finally, resulted in a
fast decrease of recombinant protein expression and its com-
plete cessation after 12–18 days post infection [131]. DIP accu-
mulation in the insect cell baculovirus expression system is
widely described and has been related to the loss of large seg-
ments of the viral genome including foreign genes.
These examples demonstrate clearly that regardless potential
changes concerning vaccine immunogenicity or safety associ-
ated to virus mutation, virus instabilities (DIP formation)
and changes in virus replication dynamics can cancel out pos-
sible benefits of continuous cultivation strategies and prevent
the application of this method for vaccine manufacturing at
any scale. Whether this is true for all viruses, which are con-
sidered for vaccination, remains an open subject of investiga-
tion. Nevertheless, hybrid processing methods combining
continuous (cell production bioreactor equipped with perfu-
sion modules) and batch operation units (virus production
bioreactor) are feasible and have already improved viral vac-
cine manufacturing [123].
Use of disposable bioreactors in vaccine production
Single-use bioreactors (SUBs) are in the focus of commercial
vaccine production since cultivation studies have shown compa-
rable cell growth kinetics and virus/recombinant protein yields
for bioreactors made out of disposable plastic compared to
stainless steel tanks [64,132–135]. For its application, there are sev-
eral chemical and physical criteria which have to be fulfilled.
Clearly, polymeric multilayer films and welds in the plastic bag
should be free of any extractables or leachables to be compliant
with pharmacopoeia standards [136] and should not bind
medium components or products. In particular, safety
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measurements regarding prevention of bag bursting are
required, not only because of product loss and spillage, but
also to comply with safety issues regarding (highly) infectious
material. Further, the supply chain of cultivation bags has to be
guaranteed and alternative suppliers are indispensable for a
licensed process.
SUBs are, in theory, relatively simple to install and univer-
sally applicable by plug and play connections. They are
replaced within shortest time after the process, saving cleaning
and sterilization steps while reducing cross-contamination
risks [137]. However, even though disposables are delivered with
qualification tests, it does not eliminate the need for process
validation studies. Nevertheless, the faster turnaround between
batches in combination with often lower initial investment
compared to fixed asset stainless steel facilities are an attractive
option to increase the production efficiency [138,139]. In addi-
tion, new production facilities relying on disposables can be
commissioned fast as the complexity involved in planning,
installation and validation of production facilities is reduced
greatly. For vaccine production, this could have significant
advantages in case of pandemics or the need to build up pro-
duction capacities in emerging or developing countries [139,140].
Accordingly, single-use solutions can be currently ordered
custom-made with different disposable sensors, diverse sparging
systems and various mechanical agitation systems (top- or
bottom-mounted impeller, rocker, orbital shaker of up to 200 l
working volume) [141]. Disposable bioreactors are currently
available at working volumes up to 500 l for rocking systems
and 2000 l for stirred tank systems [142–145]. Large-scale vaccine
production often employs even larger volumes, so producing
larger SUBs with identical configurations and proportions is
challenging, but would circumvent the use of multiple single-
use systems in parallel. However, more systems increase the risk
of leaky seams or breakage of single plastic units but also avoid
the discard of large batches. The direct transfer from stainless
steel tanks to SUBs typically diminishes over increasing vol-
umes and then requires laboratory-scale investigations from the
scratch.
An example of a vaccine facility fully equipped with dispos-
able technology is the Novavax pilot plant in Rockville, US.
The plant, with 75 million doses capacity, was equipped with
200 l wave bioreactors (GE Healthcare) to produce an insect
cell-based H5N1 influenza vaccine for evaluation in Phase I
and II clinical trials. In addition, a 1000 l SUB (Xcellerex, GE
Healthcare) was employed for scale-up toward commercial
manufacturing. The company claimed a threefold plant size
reduction and a 20-fold facility cost reduction in comparison
to egg-based or mammalian cell culture-based influenza vaccine
manufacturing [68,139]. The same disposable technology has
been recently implemented, to develop a vaccine candidate
against Zaire Ebola virus for clinical trials [146]. Another indus-
trial process employing either 200 or 50 l SUB has been
described by ProBioGen for the manufacture of a MVA
vectored-based tuberculosis vaccine candidate produced in
AGE1.CR.pIX suspension cells [14].
Expert commentary
Many new methods for viral vaccine production have been
developed over the last few years. Improvements in cell lines,
viruses, culture media, bioreactor technologies and cultivation
strategies have significantly extended the toolbox for vaccine
production. In the foreseeable future, conventional batch pro-
duction systems will be complemented with fed-batch and per-
fusion systems to increase space-time-yields in manufacturing
of vaccines for human use. Especially, the availability of new
suspension cell lines and the development of disposable cultiva-
tion methods will result in an additional boost toward process
intensification. Poorly replicating viruses, viral vectors or VLPs
now have new potential to become viable vaccine candidates
with these improvements. Regarding large-scale production, cell
concentrations exceeding 1  108 cells/ml, which maintain
high cell-specific virus yields, appear obtainable. Further
increases in titers may be achieved by multiple harvest strategies
or expanded volume fed-batch processes. Being more efficient
in cell-specific productivity should allow for smaller cultivation
units or a steady increase of vaccine doses for existing produc-
tion plants. So far, however, the potential of many approaches
has been demonstrated at laboratory scale only, and the future
will show, which concepts can be transferred successfully to
large-scale operation. To cope with an ever increasing demand
of efficacious and safe vaccines for a growing world population,
considerable efforts in research and development as well as in
large-scale manufacturing are still required.
Five-year view
As the global human vaccine market is expected to grow in the
next 5 years with an annual rate of 10–15% [147], there is a
demand for continued process development and process inten-
sification. Newly established cell lines, new bioreactor concepts
and advanced cultivation strategies will be required to make
use of the full potential in this field for the upcoming years. In
addition, a deeper biological understanding of cell growth,
virus-host cell interaction and virus replication dynamics is
required, and media development should be intensified to reach
higher cell concentrations, while maintaining cell-specific yields.
In the long run, fed-batch and perfusion systems, for some
application even continuous processes, should be established,
provided that new vaccine candidates successfully pass all clini-
cal hurdles. This will change the current vaccine supply system:
simplicity and flexibility of new production plants already
addresses newly industrialized countries like India and China,
who will significantly increase their production efforts to supply
local people and other regions with still limited access. This
trend will expand toward developing and emerging countries
utilizing small-scale facilities that are positioned in a completely
flexible way to support self-supply and independency. There-
fore, highly adjustable multi-product plants are conceivable,
most probably mobile, operating dispersed in regions according
to demands. In higher developed industrial countries, this plat-
form would allow fast reaction time, low-volume vaccine pro-
duction and simplified supply of clinical material.
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Technological advances in vaccine manufacturing will support
the implementation and expansion into new options, such as
the use of viral vectors for gene therapy or personalized medi-
cine. Finally, highly productive single-use bioreactors to manu-
facture specific vaccines for patient groups can support new
high-value drug manufacturing processes against orphan
diseases.
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Key issues
. Prior to establishment of a vaccine production process, specific aspects have to be considered to choose the appropriate cultivation
technology and operation mode. These are, inter alia, the choice of the vaccine type, a full understanding of cell substrate and virus
propagation requirements, as well as the projected number of required vaccine doses to ensure economic and technical viability.
. Despite their limitations in process monitoring and control, static cultivation systems still represent an economic platform for seed
preparation or even production of human vaccines. Mechanized support and automatic handling allow large-scale application of roller
bottles and multilayer systems.
. Bioreactors allow vaccine production under fully controlled and monitored conditions, ensuring high batch-to-batch consistency, and
processes sterility. In addition, the risk of operator errors can be reduced due to automation. Conventional stainless steel stirred tanks as
well as single-use bioreactors have a great scale-up potential, which is crucial to meet increasing vaccine demands.
. Cell culture-based vaccine production employing bioreactors has expanded manufacturing capacities in terms of larger volumes, shorter
response time, lower costs and higher process control, while ensuring product quality.
. Microcarrier technology has enabled large-scale cultivation of adherent cells in quasi-suspension conditions and facilitates media
exchange as well as certain infection strategies. However, process scale-up demands laborious bead-to-bead transfers, while process
intensification is primarily restricted to volume expansion.
. Packed-bed bioreactors representing a cost–efficient platform typically enable cell seeding at low concentrations but restrict process
monitoring. Single-use systems constitute a flexible option, whereas oxygen input is often the limiting factor for porous materials.
. Suspension culture reduces process complexity, facilitates large-scale processes and offers various options for process intensification.
Therefore, it will remain the preferred cultivation method. However, a larger portfolio of high-yield virus producing suspension cell lines
that grow in serum-free media would be desirable.
. Perfusion systems allow to achieve cell densities higher than 1  108 cells/ml which results in significant volume reductions in seed and
production bioreactors. The use of this technology in commercial vaccine manufacturing should result in considerable cost savings.
. Continuous vaccine manufacturing shows defective inferring particles accumulation, which, so far, limits viral vaccine yields. In addition,
high mutation rates of cells and viruses might restrict its use to certain limited passage numbers. However, establishment of continuous
bioprocesses for cultivation of cells expressing recombinant vaccines may be a viable option.
. Disposable technology has expanded bioprocess potential and flexibility by reduced investment cost, shorter validation times and saved
facility space. Single-use bioreactors can contribute to fulfill present and upcoming demands in vaccine production and represent
therefore a seminal alternative to traditional stainless steel tanks.
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